Liver transplantation for malignant disease has gained increasing attention as part of transplant oncology.Following the implementation of the Milan criteria,hepatocellular carcinoma(HCC)was the first generally accept...Liver transplantation for malignant disease has gained increasing attention as part of transplant oncology.Following the implementation of the Milan criteria,hepatocellular carcinoma(HCC)was the first generally accepted indication for transplantation in patients with cancer.Subsequently,more liberal criteria for HCC have been developed,and research on this topic is still ongoing.The evident success of liver transplantation for HCC has led to the attempt to extend its indication to other malignancies.Regarding perihilar cholangiocarcinoma,more and more evidence supports the use of liver transplantation,especially after neoadjuvant therapy.In addition,some data also show a benefit for selected patients with very early stage intrahepatic cholangiocarcinoma.Hepatic epithelioid hemangioendothelioma is a very rare but nonetheless established indication for liver transplantation in primary liver cancer.In contrast,patients with hepatic angiosarcoma are currently not considered to be optimal candidates.In secondary liver tumors,neuroendocrine cancer liver metastases are an accepted but comparability rare indication for liver transplantation.Recently,some evidence has been published supporting the use of liver transplantation even for colorectal liver metastases.This review summarizes the current evidence for liver transplantation for primary and secondary liver cancer.展开更多
The genetic landscape of cholangiocarcinoma(CCA)remains largely unexplored.It is one of the deadliest cancers(1),with the gold standard treatment for all anatomical forms(intrahepatic-iCCA,perihilar-pCCA and distal-dC...The genetic landscape of cholangiocarcinoma(CCA)remains largely unexplored.It is one of the deadliest cancers(1),with the gold standard treatment for all anatomical forms(intrahepatic-iCCA,perihilar-pCCA and distal-dCCA)being surgical resection(with adjuvant capecitabine also recommended in the newest guidelines)(2,3).The importance of genetic markers in terms of postoperative and oncological outcomes is being increasingly recognized,but few actionable mutations have been identified so far(2,4).This is particularly pertinent for patients with advanced/irresectable disease,who rely on systemic therapy.Survival outcomes are poor in these patients[5-year survival up to 10%-(5)]and they would profit the most from novel,targeted therapies.展开更多
文摘Liver transplantation for malignant disease has gained increasing attention as part of transplant oncology.Following the implementation of the Milan criteria,hepatocellular carcinoma(HCC)was the first generally accepted indication for transplantation in patients with cancer.Subsequently,more liberal criteria for HCC have been developed,and research on this topic is still ongoing.The evident success of liver transplantation for HCC has led to the attempt to extend its indication to other malignancies.Regarding perihilar cholangiocarcinoma,more and more evidence supports the use of liver transplantation,especially after neoadjuvant therapy.In addition,some data also show a benefit for selected patients with very early stage intrahepatic cholangiocarcinoma.Hepatic epithelioid hemangioendothelioma is a very rare but nonetheless established indication for liver transplantation in primary liver cancer.In contrast,patients with hepatic angiosarcoma are currently not considered to be optimal candidates.In secondary liver tumors,neuroendocrine cancer liver metastases are an accepted but comparability rare indication for liver transplantation.Recently,some evidence has been published supporting the use of liver transplantation even for colorectal liver metastases.This review summarizes the current evidence for liver transplantation for primary and secondary liver cancer.
文摘The genetic landscape of cholangiocarcinoma(CCA)remains largely unexplored.It is one of the deadliest cancers(1),with the gold standard treatment for all anatomical forms(intrahepatic-iCCA,perihilar-pCCA and distal-dCCA)being surgical resection(with adjuvant capecitabine also recommended in the newest guidelines)(2,3).The importance of genetic markers in terms of postoperative and oncological outcomes is being increasingly recognized,but few actionable mutations have been identified so far(2,4).This is particularly pertinent for patients with advanced/irresectable disease,who rely on systemic therapy.Survival outcomes are poor in these patients[5-year survival up to 10%-(5)]and they would profit the most from novel,targeted therapies.